Secondary Logo

Most Popular Articles

Adapted ECHO-7 virus Rigvir immunotherapy (oncolytic virotherapy) prolongs survival in melanoma patients after surgical excision of the tumour in a retrospective study

Donina, Simona; Strele, Ieva; Proboka, Guna; More

Melanoma Research. 25(5):421-426, October 2015.

Rapid BRAF mutation tests in patients with advanced melanoma: comparison of immunohistochemistry, Droplet Digital PCR, and the Idylla Mutation Platform

Bisschop, Cornelis; ter Elst, Arja; Bosman, Lisette J.; More

Melanoma Research. 28(2):96-104, April 2018.

Analysis of survival of patients treated with vemurafenib, ipilimumab and dabrafenib for advanced skin melanoma in daily clinical practice (Real-World Data): retrospective analysis of patients treated under drug/reimbursement programmes in Poland in 2013–2016

Brzozowska, Melania; Wierzba, Waldemar; Sliwczynski, Andrzej; More

Melanoma Research. 28(1):52-55, February 2018.

MGMT methylation correlates with melphalan pelvic perfusion survival in stage III melanoma patients: a pilot study

Guadagni, Stefano; Fiorentini, Giammaria; Clementi, Marco; More

Melanoma Research. 27(5):439-447, October 2017.

Sarcoid-like reactions in patients receiving modern melanoma treatment

Dimitriou, Florentia; Frauchiger, Anna L.; Urosevic-Maiwald, Mirjana; More

Melanoma Research. 28(3):230-236, June 2018.

Whole-exome sequencing identifies recurrent SF3B1 R625 mutation and comutation of NF1 and KIT in mucosal melanoma

Hintzsche, Jennifer D.; Gorden, Nicholas T.; Amato, Carol M.; More

Melanoma Research. 27(3):189-199, June 2017.

Postsurgical treatment landscape and economic burden of locoregional and distant recurrence in patients with operable nonmetastatic melanoma

Tarhini, Ahmad; Ghate, Sameer R.; Ionescu-Ittu, Raluca; More

Melanoma Research. 28(6):618-628, December 2018.

Decreased expression of NKG2D, NKp46, DNAM-1 receptors, and intracellular perforin and STAT-1 effector molecules in NK cells and their dim and bright subsets in metastatic melanoma patients

Mirjacic Martinovic, Katarina M.; Babovic, Nada Lj.; Džodic, Radan R.; More

Melanoma Research. 24(4):295-304, August 2014.

The impact of patient characteristics and disease-specific factors on first-line treatment decisions for BRAF-mutated melanoma: results from a European expert panel study

Ascierto, Paolo A.; Bastholt, Lars; Ferrucci, Pier F.; More

Melanoma Research. 28(4):333-340, August 2018.

A combination of high dose rate (10X FFF/2400 MU/min/10 MV X-rays) and total low dose (0.5 Gy) induces a higher rate of apoptosis in melanoma cells in vitro and superior preservation of normal melanocytes

Sarojini, Sreeja; Pecora, Andrew; Milinovikj, Natasha; More

Melanoma Research. 25(5):376-389, October 2015.

Enhancing the prognostic role of melanoma sentinel lymph nodes through microscopic tumour burden characterization: clinical usefulness in patients who do not undergo complete lymph node dissection

Borgognoni, Lorenzo; Bellucci, Francesco; Urso, Carmelo; More

Melanoma Research. 29(2):163-171, April 2019.

Evaluation of the prognostic significance of serum galectin-3 in American Joint Committee on Cancer stage III and stage IV melanoma patients

Vereecken, Pierre; Awada, Ahmad; Suciu, Stefan; More

Melanoma Research. 19(5):316-320, October 2009.

Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland

Mangana, Joanna; Cheng, Phil F.; Kaufmann, Corina; More

Melanoma Research. 27(4):358-368, August 2017.

Treatment patterns of adjuvant interferon-α2b for high-risk melanoma: a retrospective study of the Grupo Español Multidisciplinar de Melanoma – Prima study

Espinosa, Enrique; Soriano, Virtudes; Malvehy, Josep; More

Melanoma Research. 26(3):278-283, June 2016.

Vitamin C downregulates interleukin-18 production by increasing reactive oxygen intermediate and mitogen-activated protein kinase signalling in B16F10 murine melanoma cells

Cho, Daeho; Hahm, Eunsil; Kang, Jae Seung; More

Melanoma Research. 13(6):549-554, December 2003.

Potential clinical and immunotherapeutic utility of talimogene laherparepvec for patients with melanoma after disease progression on immune checkpoint inhibitors and BRAF inhibitors

Chesney, Jason; Imbert-Fernandez, Yoannis; Telang, Sucheta; More

Melanoma Research. 28(3):250-255, June 2018.

Stereotactic radiosurgery combined with immune checkpoint inhibitors or kinase inhibitors for patients with multiple brain metastases of malignant melanoma

Stera, Susanne; Balermpas, Panagiotis; Blanck, Oliver; More

Melanoma Research. 29(2):187-195, April 2019.

BRAF inhibition for advanced locoregional BRAF V600E mutant melanoma: a potential neoadjuvant strategy

Sloot, Sarah; Zager, Jonathan S.; Kudchadkar, Ragini R.; More

Melanoma Research. 26(1):83-87, February 2016.

Economic burden of advanced melanoma in France, Germany and the UK: a retrospective observational study (Melanoma Burden-of-Illness Study)

Grange, Florent; Mohr, Peter; Harries, Mark; More

Melanoma Research. 27(6):607-618, December 2017.

Nivolumab monotherapy or in combination with ipilimumab for metastatic melanoma: systematic review and meta-analysis of randomized-controlled trials

Menshawy, Amr; Eltonob, Abdelrahman A.; Barkat, Sarah A.; More

Melanoma Research. 28(5):371-379, October 2018.

Coexpression of major histocompatibility complex class II with chemokines and nuclear NFκB p50 in melanoma: a rational for their association with poor prognosis

Martins, Isabelle; Sylla, Khaoussou; Deshayes, Frederique; More

Melanoma Research. 19(4):226-237, August 2009.

Show: